Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
  • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/10—Transferases (2.)
  • C12N9/1048—Glycosyltransferases (2.4)
  • C12N9/1051—Hexosyltransferases (2.4.1)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to a compound selected from a polynucleotide coding for the glycogen debranching enzyme (GDE), a vector and a host cell genetically engineered so as to express the GDE enzyme.
• GDE glycogen debranching enzyme
• the present invention further relates to the use of the compound for the treatment of a glycogenosis (GSD), preferably GSDIII.
• Glycogenoses are a group of at least fifteen rare metabolic diseases due to alterations of enzymes that act at different levels of the metabolic pathway of glycogen degradation.
• Glycogen represents a storage form of sugars that the body uses according to need to release glucose in order to maintain blood glucose at normal levels during fasting and/or for energy purposes for muscular contraction.
• An accumulation of glycogen in tissues causes severe alterations, mainly in the liver, in muscles and in other organs.
• glycogenosis type III (GSDIII, or Cori or Forbes disease), is an ultra rare disease, with an estimated prevalence of about ⁇ 1 out of 80,000-100,000 born, due to the absence of the glycogen debranching enzyme (GDE).
• GDE glycogen debranching enzyme
• GDE is a cytoplasmic monomeric protein with two distinct catalytic activities: it contains a transferase domain and a glucosidase domain.
• the lack or an alteration of the activity of the GDE enzyme leads to abnormal glycogen with shorter chains (called p hosphorylase-limit dextrin, PLD) which accumulates in skeletal and/or heart muscle and/or in the liver.
• PLD p hosphorylase-limit dextrin
• the disease manifests itself a few months after birth or during childhood with an enlargement of the liver, hypoglycaemia and retarded growth.
• the muscles generally weaken starting from the second-third decade of life and, in addition to muscle hypotonia, some affected individuals can develop a hypertrophic cardiomyopathy over time.
• the symptoms present themselves with a highly variable severity.
• the disease is caused by mutations of the “AGL” ( amylo-1,6 - glucosidase, 4-alpha-glucanotransferase) gene, which codes for the GDE enzyme, and is transmitted in an autosomal recessive manner: it is necessary that both genes, of paternal and maternal origin, lead to a pathological change in the sequence in order for the disease to manifest itself.
• the parents are therefore healthy carriers.
• ERT Enzyme replacement therapy
• the cDNA of the AGL gene was divided into two parts (with an overlapping region) and it was necessary to introduce a step of a homologous recombination process, which partly nullifies the advantage of the high transfection efficiency of the viral vector.
• a first aspect of the present invention relates to a compound selected from: a) a polynucleotide coding for a glycogen debranching enzyme (GDE), a recombinant or synthetic derivative of GDE, a fragment or an allele variant of said GDE; b) a vector comprising said polynucleotide; c) a genetically engineered host cell that expresses said polynucleotide.
• GDE glycogen debranching enzyme
• a second aspect of the present invention relates to a pharmaceutical composition comprising the compound described above.
• a third aspect of the present invention relates to the compound as described above for use as a medicament.
• a fourth aspect of the present invention relates to the compound described above or the recombinant GDE enzyme for use in the treatment of a glycogenosis (GSD).
• GSD glycogenosis
• the GSD is GSDIII (Cori or Forbes disease).
• a fifth aspect of the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising the compound described above and/or the GDE enzyme, for use in the treatment of a glycogenosis (GSD).
• the composition is preferably administered in association or in combination with electropermeabilisation of the plasma membrane.
• a further aspect of the present invention relates to a method for the treatment of a GSD, preferably GSDIII (Cori or Forbes disease).
• Said method comprises at least a step of administering an effective amount of the compound and/or of the GDE enzyme according to the present invention or of a composition that comprises the compound and/or GDE enzyme as described above, to a subject (individual) affected or suspected to be affected by a GSD, preferably GSDIII, possibly in combination with electropermeabilisation.
• Figure 1 shows the expression of the GDE protein obtained from the expression of the sAGL (sGDE) gene in different E. coli strains transformed with suitable expression vectors comprising the codon-optimised AGL gene ( sAGL ⁇ , SEQ ID NO. 1 ):
• TSP 10 pg total soluble proteins extracted from bacterial cells BL21 and BL21/Gro7, containing the constructs pQE-30-His6-s/tGZ. or pQE50 -sAGL after induction of expression at 37 °C or 28 °C for 16 hours.
• Figure 2 shows a comparison between the recombinant sGDE protein purified from bacteria (Flis6-sGDE) and the endogenous GDE protein present in red cells and white cells of human blood;
• Figure 3 shows the result of the enzymatic test for assessing glycogen debranching activity.
• C3PV cell line of human fibroblasts
• WBC human white blood cells
• GM02523 fibroblasts from GSDIII patients.
• Figure 4 shows the stability of the recombinant sGDE enzyme purified from bacteria.
• (+) rat liver homogenate;
• 1 sGDE fresh preparation;
• 2 sGDE stored at 4 °C for 12 months;
• 3 lyophilised sGDE resuspended in a reaction buffer.
• Figure 5 shows the overexpression of the recombinant GDE enzyme in human cells (HEK 293) in culture after transfection with the plasmid containing the codon-optimised s AGL gene, pVAX-s AGL (H10, H11 ) and with the one containing the AGL gene with the human sequence ( hAGL ), pVA X-hAGL (B4) compared to non-transfected cells (control), evaluated by immunofluorescence microscopy).
• Figure 6 shows the overexpression of the GDE recombinant enzyme in HEK cells transfected with the pVA X-sAGL (H10, H11 ) plasmid compared to non-transfected cells (control) or those transfected with the pVA X-hAGL (B4) plasmid evaluated by immunoblotting (WB, “Western blot) and Ponceau red staining (control);
• Figure 7 shows the increase in glycogen debranching activity in HEK cells transfected with the pVA X-sAGL (H10 and H11) plasmid and with the pVA X-hAGL (B4) plasmid compared to non- transfected cells (C) of the same type, verified by means of a specific enzymatic test.
• the positive control is represented by the recombinant GDE protein purified from bacteria (His6- sGDE).
• Figure 8 shows the expression of the recombinant GDE enzyme in GDE-deficient cells (fibroblasts derived from GSDIII patients), GM00111 (a.) and GM02523 (b.) after transfection with the pVA X-sAGL plasmid using the transfecting agent Mirus 1 (column 1 ) or Mirus 2 (column 2).
• C- non-transfected cells (negative control).
• the recombinant His6-sGDE protein purified from bacteria (sGDE) and the HEK cells (C+) represent the positive control.
• Figure 9 shows the increase in/restoration of glycogen debranching activity in GM00111 (a.) and GM02523 (b.) cells after transfection with the pVA X-sAGL plasmid mediated by transfecting agents (Mirus 1 or Mirus 2), and verified by means of a specific enzymatic test.
• C- non-transfected cells, negative control;
• C+ HEK cells, positive control.
• orthologs means similar genes or proteins that can be found in mutually correlated organisms.
• recombinant means a protein obtained following the transcription and translation of a fragment of recombinant DNA.
• recombinant DNA means a DNA sequence obtained artificially by chemical synthesis or by combining genetic material of different origins, as may occur in the case of a plasmid containing a gene of interest.
• electroperation or “electropermeabilisation” (reversible) means the application of a sudden electric discharge to cells and/or tissues and/or organs with the aim of opening the plasma membrane of the cells simultaneously in numerous points, thereby enabling DNA molecules to penetrate.
• polynucleotide coding for a glycogen debranching enzyme or “sAGL” means the codon-optimised AGL.
• hAGL means the non-codon-optimised human AGL gene.
• sGDE means the GDE protein obtained from the expression of the sAGL gene.
• His6-sGDE means: the sGDE protein fused to a 6 histidine tag at the N-terminus.
• hGDE means the GDE protein obtained from the expression of the hAGL gene.
• a first aspect of the present invention relates to a compound selected from: a) a polynucleotide coding for a glycogen debranching enzyme (GDE), or a recombinant or synthetic derivative of GDE, a fragment or an allele variant of said GDE; b) a vector comprising said polynucleotide; c) a genetically engineered host cell that expresses said polynucleotide
• GDE glycogen debranching enzyme
• the polynucleotide coding for said GDE is selected from DNA and RNA; it is preferably DNA.
• the polynucleotide comprises a nucleotide sequence substantially homologous or identical to SEQ ID N0.1 (Table 1).
• the polynucleotide comprises a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous or identical to SEQ ID NO. 1.
• the polynucleotide preferably comprises a nucleotide sequence that is at least 80%, more preferably at least 90% homologous or identical to SEQ ID NO. 1 .
• the polynucleotide consists in a nucleotide sequence substantially homologous or identical to SEQ ID N0.1.
• the polynucleotide consists in a nucleotide sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous or identical to SEQ ID NO. 1.
• the polynucleotide preferably consists in a nucleotide sequence that is at least 80%, more preferably at least 90% homologous or identical to SEQ ID NO. 1 .
• the polynucleotide comprises at least one constitutive or tissue-specific promoter capable of controlling the expression of the cDNA coding for the AGL gene.
• the vector comprising the polynucleotide described above is selected from: viral vector, plasmid, viral particles and phage.
• the vector is a plasmid vector.
• the genetically engineered host cell that expresses the polynucleotide described above is selected from: bacterial cell, fungal cell, animal cell, insect cell and plant cell; the host cell is preferably an animal cell.
• a second aspect of the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising the compound as defined above.
• the composition of the present invention can further comprise at least one pharmacologically acceptable excipient, i.e. a compound, acceptable for pharmaceutical use, that is useful in the preparation of the composition and is generally biologically safe and nontoxic.
• a third aspect of the present invention relates to the compound as described above in detail for use as a medicament.
• a fourth aspect of the present invention relates to the compound as described above in detail or the glycogen debranching enzyme (GDE), an ortholog or synthetic GDE enzyme, for use in the treatment of a glycogenosis (GSD).
• GDE glycogen debranching enzyme
• GSD glycogenosis
• the GSD is preferably characterised by an accumulation of glycogen in muscle, the liver, heart and/or central nervous system.
• the GSD is selected from: GSDIa (Von Gierke disease), GSDI non-a, GSDII (Pompe disease), GSDIIb (Danon disease), GSDIII (Cori or Forbes disease), GSDIV (Andersen disease), GSDV (McArdle disease), GSDVI (Hers disease), GSDVII (Tarui disease), GSDIX, GSDXI (Fanconi-Bickel syndrome), GSDXI (aldolase deficiency), GSDXIII and GSDO.
• the GSD is GSDIII (Cori or Forbes disease).
• the GDE enzyme comprises an amino acid sequence that is substantially identical to SEQ ID N0.2.
• the GDE enzyme comprises an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO. 2.
• the GDE enzyme comprises an amino acid sequence that is at least 80%, more preferably at least 90% identical to SEQ ID NO. 2.
• the GDE enzyme consists in an amino acid sequence that is substantially identical to SEQ ID NO. 2.
• the GDE enzyme consists in an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO. 2.
• the GDE enzyme consists in an amino acid sequence that is at least 80%, more preferably at least 90% identical to SEQ ID NO. 2.
• the GDE enzyme comprises modifications to the N- terminal and/or C-terminal region, for example apt to increase the activity of the GDE enzyme. Said modifications are preferably selected from deletions, additions, alterations of amino acids and combinations thereof.
• said GDE can be modified, preferably in its primary structure, by acetylation, carboxylation, phosphorylation and combinations thereof.
• said GDE enzyme is conjugated/bound to a molecule, a metal, a marker, for example proteins, for the preparation of fusion proteins.
• said GDE enzyme is modified by means of molecular biology techniques in order to improve its resistance to proteolytic degradation and/or to optimise its solubility or to improve its pharmacokinetic characteristics.
• said GDE enzyme can be modified with the aim of facilitating or improving delivery, preferably by means of PEGylation, or using container/shuttle/carrier systems, preferably such as liposomes, micelles, capsules, emulsions, matrices, gels and the like.
• said GDE enzyme is coated with a structure capable of improving its stability and/or half-life and/or water solubility and/or immunological characteristics.
• Said structure is for example a pH-sensitive microsphere, a microsphere, a micro-tablet, a liposome, or else nano-delivery systems with conductive particles mediated by pulsed electric fields (PEFs) or fusion with cell-penetrating peptides (CPPs).
• the enzyme is obtained by means of recombinant DNA techniques known to the person skilled in the art, preferably by cloning the polynucleotide (cDNA) coding for GDE in a plasmid vector for the expression of the recombinant enzyme in bacteria.
• cDNA polynucleotide
• the GDE enzyme is obtained by cloning the non- codon-optimised human polynucleotide ( hAGL ) or the polynucleotide coding for GDE comprising SEQ ID NO. 1 ( sAGL ), as described above in detail.
• said GDE enzyme is synthesised by means of conventional techniques for protein synthesis which are known to the skilled person.
• the protein can be synthesised by chemical synthesis using solid-phase peptide synthesis.
• the GDE enzyme is isolated or purified with methods known to the person skilled in the art.
• the GDE enzyme can be purified by means of biochemical methods, such as filtration, affinity, immunoaffinity or by high-efficiency liquid chromatography (HPLC, FIP-HPLC, ion-exchange HPLC, size-exclusion HPLC).
• biochemical methods such as filtration, affinity, immunoaffinity or by high-efficiency liquid chromatography (HPLC, FIP-HPLC, ion-exchange HPLC, size-exclusion HPLC).
• the compound or the GDE enzyme is delivered to a target tissue, preferably a tissue that contains accumulations of anomalous glycogen (PLD).
• the target tissue is preferably selected from: muscle, liver, heart and/or central nervous system; more preferably, the muscle is selected from: skeletal muscle, heart muscle and/or diaphragm.
• the polynucleotide or the vector, as described above is delivered to a target tissue that contains accumulations of glycogen.
• the polynucleotide or the vector, as described above, is preferably delivered to a target tissue that contains accumulations of glycogen in association/combination with electropermeabilisation, i.e. with the application of electric fields, preferably pulsed electric fields (PEFs).
• PEFs pulsed electric fields
• the pulsed electric fields are applied with a combination of high voltage electric pulses and low voltage pulses.
• a fifth aspect of the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising the compound or the GDE enzyme as defined above for use in the treatment of a glycogenosis.
• the composition of the present invention can further comprise at least one pharmacologically acceptable excipient, i.e. a compound, acceptable for pharmaceutical use, that is useful in the preparation of the composition and is generally biologically safe and nontoxic.
• the composition comprises at least a further therapeutic agent for the treatment of GSDs, in particular GSDIII (Cori or Forbes disease).
• the composition is formulated in liquid form, preferably as a solution, emulsion or sterile suspension.
• the composition is in lyophilised form, to be reconstituted to obtain a liquid formulation.
• the composition is administered by a parenteral route selected from the intravenous, subcutaneous and intramuscular routes.
• the composition preferably comprising the polynucleotide or the vector, as described above, is administered locally, preferably by local injection, directly into the tissue/organ to be treated.
• composition is preferably administered as a bolus or by continuous infusion.
• the tissue/organ to be treated is a tissue/organ that contains accumulations of glycogen.
• the tissue/organ to be treated is preferably selected from: muscle, liver, heart and/or central nervous system; more preferably, the muscle is selected from: skeletal muscle, heart muscle and/or diaphragm.
• the composition is administered in association or in combination with electropermeabilisation.
• the composition preferably comprising the polynucleotide or the vector, preferably the vector, is administered into the target tissue/organ in association or in combination with electropermeabilisation, i.e. with the application of electric fields, preferably pulsed electric fields (PEFs).
• electric fields preferably pulsed electric fields (PEFs).
• the electropermeabilisation is preferably applied locally, i.e. to the tissue/organ to be treated. In one embodiment, the electropermeabilisation is applied directly to the tissue/organ that contains accumulations of glycogen.
• the pulsed electric fields are applied with a combination of high voltage pulses and low voltage pulses.
• Electropermeabilisation is capable of increasing, in a transient manner, the permeability of cell membranes, making possible the entry of the polynucleotide or vector into cells and into the treated tissues/organs.
• a non-viral approach for example using a plasmid vector in association or in combination with electroporation, proves to be particularly advantageous, as it is safer than viral vectors and enables better control of the diffusion of the vector in tissues/organs.
• a local treatment with non-viral methods, such as plasmids, in association or in combination with electroporation increases the effectiveness of the therapy and reduces the health costs and the adverse effects due to systemic administration.
• the compound of the present invention delivered by means of (non-viral) physical or chemical methods, is capable of significantly increasing the expression of the GDE enzyme in the treated cells.
• the composition is formulated for enteral administration, preferably for oral administration.
• the composition is formulated in solid form, preferably in the form of pills, capsules, tablets, granular powder, hard-shelled capsules, orally dissolving granules, sachets or lozenges.
• a further aspect of the present invention relates to a method for the treatment of a GSD, preferably GSDIII (Cori or Forbes disease).
• Said method comprises at least a step of administering an effective amount of the compound or of the GDE enzyme according to the present invention or of a composition that comprises it, as described above in detail, to a subject (individual) affected or suspected to be affected by a GSD, preferably by GSDIII.
• the composition is administered intravenously as a bolus or by continuous infusion.
• the composition is preferably administered by local injection directly into the tissue affected by an accumulation of anomalous glycogen.
• the composition is administered by injection or infusion in association or in combination with electropermeabilisation.
• the composition comprising the polynucleotide or the vector, preferably the vector, more preferably the plasmid, is administered in association or in combination with electroporation (also known as “electropermeabilisation”), i.e. with the application of electric fields, preferably pulsed electric fields (PEFs).
• electroporation also known as “electropermeabilisation”
• electric fields preferably pulsed electric fields (PEFs).
• the electropermeabilisation is applied locally, i.e. on the tissue/organ to be treated.
• the electropermeabilisation is applied directly to the tissue/organ that contains accumulations of glycogen.
• the pulsed electric fields are applied with a combination of high voltage pulses and low voltage pulses.
• the synthetic sAGL gene (codon-optimised for expression in cells of the insect Spodoptera frugiperda) encoding the sGDE enzyme was synthesised by the American Genscript Co. The gene was then cloned under the control of inducible promoters in suitable plasmid vectors for the expression of the recombinant enzyme in bacteria, fused or not fused to a six histidine tag (His6) at the N-terminus, to enable purification by affinity chromatography. These vectors were used for the transformation of different strains of E. coli. Following induction of protein expression at different culture temperatures, the expression of a 176 KDa protein was obtained only when the His6 “tag” was present (Fig. 1 ). In the absence of the “tag”, the resulting GDE protein is smaller in size (about 120 KDa) (Fig. 1).
• the Flis6-sGDE protein expressed in bacteria was purified by affinity chromatography and showed approximately the same molecular weight as the human GDE protein present in the blood cells of healthy persons (Fig. 2).
• the maintenance of catalytic activity was assessed using a protocol adapted from the one used for diagnosis at the Department of Clinical Biochemistry of the University of Manchester, NFIS Foundation Trust, Manchester, the United Kingdom and made available by Fiona Ivison.
• the glycogen debranching enzyme shows two distinct catalytic activities, transferasic and glucosidasic.
• the test used measures the glucosidasic activity of the enzyme, which, by acting at the level of the branching points of the specific substrate thereof (PLD, phosphorylase-limit dextrin), releases molecules of glucose.
• PLD phosphorylase-limit dextrin
• These molecules following a colorimetric reaction with the enzymes glucose oxidase and peroxidase and ABTS (2,2'-azino-bis(3- ethylbenzthiazoline-6-sulfonic acid) are measured by means of spectrophotometric readings at a wavelength of 740 nm: the absorbance values measured are in fact directly correlated with the concentration of glucose molecules released by the enzyme.
• a human cell line with a GDE deficiency GM02523, fibroblasts derived from GSDIII patients was used as a negative control for the test.
• Flis6-sGDE is endowed with considerable stability, as demonstrated by the maintenance of catalytic activity even after storage at 4 °C for 12 months or after lyophilisation (Fig. 4).
• the cDNA with the sequence optimised for expression in insect cells and the cDNA with the original sequence of the human AGL gene were cloned in a vector for expression in mammal cells, obtaining the constructs pVA X-sAGL and pVA X-hAGL, respectively.
• Intracellular delivery of these constructs was achieved with chemical methods (cationic liposome formulations, Lipofectamine) on a human cell line (human embryonic kidney cells 293, FIEK). Following transfection, only the synthetic sequence, not the original one of the human gene, showed to be expressed at high levels (Fig. 5, 6).
• the transfected human cells also showed a greater catalytic activity compared to the ‘background’ (in fact, the FIEK cells express GDE at low levels) (Fig. 7).
• GDE-deficient human cell lines (GM00111 and GM02523), characterised by us at a biochemical and ultrastructural level ( data not shown), were used for experiments on delivery by means of Lipofectamine.
• the transfection did not have a positive result ( data not shown) and, for this reason, two new transfecting agents (MIRUS 1 : TranslT-X2® System; MIRUS 2: -TranslT®-2020 Reagent) were experimented with on these lines.
• MIRUS 1 TranslT-X2® System
• MIRUS 2 -TranslT®-2020 Reagent

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Plant Substances (AREA)
• Enzymes And Modification Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=71452543

Family Applications (1)

Country Status (3)

Family Cites Families (3)

• 2020
  • 2020-02-19 IT IT102020000003371A patent/IT202000003371A1/it unknown
• 2021
  • 2021-02-17 WO PCT/IB2021/051322 patent/WO2021165841A1/en unknown
  • 2021-02-17 EP EP21712896.6A patent/EP4106801A1/de active Pending

Also Published As

Similar Documents

Legal Events